WHO issues alert for 4 India-made cough syrups; check symptoms here

WHO has asked not to use these four products until analysed by the relevant national regulatory authorities

WHO issues alert for India-made cough syrups; check symptoms here
BS Web Team
2 min read Last Updated : Oct 05 2022 | 11:46 PM IST
On Wednesday, World Health Organization (WHO) issued an alert over four substandard pediatric syrups, which could be the reason behind the deaths of 66 children in The Gambia.

According to WHO, substandard medical products fail to meet their quality standards or specifications and are, therefore, "out of specification". The four mentioned products are Promethazine Oral Solution, Kofexmalin Baby Cough Syrup, Makoff Baby Cough Syrup and Magrip N Cold Syrup. 

All these four products are manufactured in Haryana by Maiden Pharmaceuticals Limited. The company manufactures medicines at its facilities in India, which it then sells domestically and exports to countries in Asia, Africa and Latin America, according to its website. To date, the stated manufacturer has not provided guarantees to WHO on the safety and quality of these products.

"Laboratory analysis of samples of each of the four products confirms that they contain unacceptable amounts of diethylene glycol and ethylene glycol as contaminants. To date, these four products have been identified in The Gambia but may have been distributed, through informal markets, to other countries or regions," WHO said in the alert statement.

According to the agency, Diethylene glycol and ethylene glycol are toxic to humans when consumed and can prove fatal. Harmful effects can include abdominal pain, vomiting, diarrhoea, inability to pass urine, headache, altered mental state, and acute kidney injury.

WHO has asked not to use these four products until analysed by the relevant national regulatory authorities. The agency has also requested to increase surveillance within the supply chains of countries and regions.

The deaths have shaken the tiny West African nation, which is already dealing with multiple health emergencies, including measles and malaria, Reuters reported.

Medical officers in the Gambia raised the alarm in July after several children began falling ill with kidney problems three to five days after taking a locally-sold paracetamol syrup. By August, 28 had died, but health authorities said the toll would likely rise. Now 66 are dead, WHO said on Wednesday.

Check the WHO's notification here.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :World Health OrganizationWHOGambiaIndian pharma companies

Next Story